New pain block could cut opioid use after lung transplants
NCT ID NCT07641647
First seen Jun 12, 2026 · Last updated Jun 22, 2026 · Updated 1 time
Summary
This study tests whether a long-acting form of the numbing drug bupivacaine (liposomal bupivacaine) can reduce pain and the need for strong painkillers after a lung transplant. Eighty-eight adults getting a double lung transplant will receive a nerve block either with or without the liposomal version. Researchers will track pain scores and opioid use for three days after surgery to see if the liposomal drug offers better relief.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAIN MANAGEMENT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Second Affiliated Hospital of Zhejiang University anesthesiology department
Hangzhou, Zhejiang, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
liposomal bupivacaine
What this could lead to
If it works, this could offer better pain control and less reliance on opioids after lung transplant surgery.
What could go wrong
This is a small, early-phase trial (88 people) testing a known drug in a new setting. Results may not apply to all patients, and the drug may not significantly improve pain or reduce opioid use.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.